Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony- stimulating factor

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1921-1929

  Shetye, Jayant ^a   Ragnhammar, Peter ^a   Liljefors, Maria ^a   Christensson, Birger ^a   Frödin, Jan Erik ^a   Biberfeld, Peter ^a   Mellstedt, Håkan ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EDRECOLOMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BIOPSY; COLORECTAL NEOPLASMS; COMPLEMENT SYSTEM PROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPHILS; T-LYMPHOCYTES;

EID: 0031848291     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Herlyn, D., Steplewski, Z., Herlyn, M., and Koprowski, H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res., 40: 717-721, 1980.
2. Ragnhammar, P., Fagerberg, J., Frödin, J-E., Hjelm, A-L., Lindemalm, C., Magnusson, I., Masucci, G., and Mellstedt, H. Effect of the monoclonal antibody 17-1A and granulocyte monocyte colony stimulating factor in patients with colorectal carcinoma. Long lasting complete remissions can be induced. Int. J. Cancer, 53: 751-758, 1993.
3. Ragnhammar, P., Frödin, J-E., Hjelm, A-L., Fagerberg, J., Wersäll, P., Lindemalm, C., Fox, K., Magnusson, I., Ewerth, S., Ahlberg, J., Thor, K., Secher, E., and Mellstedt, H. Different dose regimens of the mouse monoclonal antibody 17-1A alone for therapy of patients with metastatic colorectal carcinoma. Int. J. Oncol., 7: 1049-1056, 1995.
4. Adams, D. O., Hall, T., Steplewski, Z., and Koprowski, H. Tumors undergoing rejection induced by monoclonal antibodies of the IgG2A isotope contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc. Natl. Acad. Sci. USA, 81: 3506-3510, 1984.
5. Herlyn, D. M., and Koprowski, H. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int. J. Cancer, 27: 769-774, 1981.
6. Trauth, B. C., Klas, C., Peters, A. M. J., Matzku. S., Möller, P., Falk, W., Debatin, K. M, and Krummer, P. H. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-305, 1989.
7. Jerne, N. K. Towards a network theory of the immune system. Ann. Immunol., 124: 373-389, 1974.
8. Ragnhammar, P., Fagerberg, J., Frödin, J-E., Wersäll, P., Hansson, L-O., and Mellstedt, H. Granulocyte monocyte colony stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies to therapeutic monoclonal antibodies. Cancer Immunol. Immunother., 40: 367-375, 1995.
9. Fagerberg, J., Frödin, J-E., Wigzell, H., and Mellstedt, H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotype antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol. Immunother., 37: 264-270, 1993.
10. Fagerberg, J., Ragnhammar, P., Liljefors, M., Hjelm, A-L., Mellstedt H., and Frödin, J-E. Humoral anti-idiotypic and anti-anti-idiotypic immune responses in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol. Immunother., 42: 81-87, 1996.
11. Villeval, J. L., Duhrsen, U., Morstyn, G., and Metcalf, D. Effect of recombinant human granulocyte monocyte colony stimulating factor on progenitor cells in patients with advanced malignancy. Br. J. Haematol., 74: 36-44, 1990.
12. Munn, D. H., and Cheung, N. K. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony stimulating factor. J. Exp. Med., 172: 231-237, 1990.
13. Lieschke, G. J., and Burgess, A. W. Granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor. N. Engl. J. Med., 327: 28-35, 1992.
14. Gasson, J. C., Weisbart, R. H., Kaufman, S. E., Clark, S. C., Hewick, R. M., Wong, G. G., and Golde, D. W. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science (Washington DC), 226: 1339-1342, 1984.
15. Masucci, G., Wersäll, P., Ragnhammar, P., and Mellstedt, H. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity. Cancer Immunol. Immunother., 29: 288-292, 1989.
16. Liesveld, J. L., Abboud, C. N., Looney, R. J., Ryan, D. H., and Brennan, J. K. Expression of IgG Fc receptors in myeloid leukaemic cell lines. Effect of colony-stimulating factors and cytokines. J. Immunol., 140: 1527-1533, 1988.
17. Morrissey, P. J., Bressler, L., Park, L. S., Alpert, A., and Gillis, S. Granulocyte-macrophage colony stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol., 139: 113-119, 1987.
18. Caux, C., Desutter-Dambuyant, C., Schmitt, D., and Banchereau, J. Granulocyte monocyte colony stimulating factor and tumor necrosis factor cooperate in the generation of dendritic Langerhans cells. Nature (Lond.), 360: 258-261, 1992.
19. Frödin J-E., Harmenberg, U., Biberfeld, P., Christensson, B., Lefvert, A-K., Riger, Ä., Shetye, J., Wahren, B., and Mellstedt, H. Clinical effects of monoclonal antibodies (MA17-1A) in patients with metastatic colorectal carcinoma. Hybridoma, 7: 309-321, 1988.
20. Böyum, A. A. One stage procedure for isolation of granulocytes and lymphocytes from human blood. Scand. J. Clin. Lab. Invest. Suppl., 97: 51-76, 1968.
21. Lindemalm, C., Mellstedt, H., Biberfeld, P., Björkholm, M., Christensson, B., Holm, G., Johansson, B., and Sundblad, R. Blood and lymph node T lymphocytes subsets in non-Hodgkin's lymphomas. Scand. J. Haematol., 30: 68-78, 1983.
22. Shetye, J., Frödin, J-E., Christensson, B., Grant, C., Jacobsson, B., Sundelius, S., Sylvén, M., Biberfeld, P., and Mellstedt, H. Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb17-1A). Cancer Immunol. Immunother., 27: 154-162, 1988.
23. + lymphocytes. J. Immunol., 144: 574-582, 1990.
24. Goodman, G. E., Hellström, I., Grodzinsky, L., Nicaise, C., Kulander, B., Hummel, D., and Hellström, K-E. Phase I trial of murine monoclonal antibody L6 in breast, colon and lung cancer. J. Clin. Oncol., 8: 1083-1092, 1990.
25. Garcia, C. F., Lowder, J., Meeker, T. C., Bendl, J., Levy, R., and Warnke, R. A. Differences in "host infiltrates" among lymphoma pa-tients treated with anti-idiotype antibodies: correlation with treatment response. J. Immunol., 135: 4252-4260, 1985.
26. Bajorin D. F., Chapman, P. B., Wong, G. Y., Cody, B. V., Cardon-Cardo, C., Dantes, L., Templeton, M. A., Scheinberg, D., Oettgen, H. F, and Houghton, A. N. Treatment with high dose mouse monoclonal (anti GD3) antibody R24 in patients with metastatic melanoma. Melanoma Res., 2: 355-362, 1992.
27. Cohen, P. J., Lotze, M. T., Roberts, J. R., Rosenberg, S. A., and Jaffe, E. S. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T cell infiltration and HLD-DR expression. Am. J. Pathol., 129: 208-216, 1987.
28. Rubin, J. T., Elwood, L. J., Rosenberg, S. A., and Lotze, M. T. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res., 49: 7086-7092, 1989.
29. Fagerberg, J., Frödin, J-E., Ragnhammar, P., Steinitz, M., Wigzell, H., and Mellstedt, H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy? Cancer Immunol. Immunother., 38: 149-159, 1994.
30. Fagerberg, J., Hjelm, A-L., Ragnhammar, P., Frödin, J-E., Wigzell, H., and Mellstedt, H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res., 55: 1824-1827, 1995.
31. Kosmas, C., Epenetos, A. A., and Courtenay-Luck, N. S. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer (Phila.), 73: 3000-3010, 1994.
32. Pham, C. T., and Ley, T. J. The role of granzyme B cluster proteases in cell-mediated cytotoxicity. Semin. Immunol., 9: 127-133, 1997.
33. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, I., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.